Response to olaparib in breast and ovarian cancer
Olaparib is an oral antitumoral drug that is prescribed for the treatment of patients with mutations in the BRCA1 / 2 genes, which may be present in some ovarian, breast, prostate and fallopian tube cancers.
The FDA has approved olaparib for the treatment of patients with mutations in the BRCA1 and BRCA2 genes.
The mechanism of action of olaparib is based on its potent inhibitory character of human poly (ADP-ribose) polymerase (PARP-1, PARP-2, and PARP-3) enzymes. It has been shown that the drug inhibits the growth of tumor cell lines selected in vitro and the growth of tumors in vivo.
Hypersensitivity to olaparib.
Lactation during treatment and one month after the last dose.
Given the hematological toxicity, it is recommended to perform tests at the beginning, followed by a monthly monitoring, of the complete blood count during the first 12 months of treatment and periodically from this moment. It is also associated with myelodysplastic syndrome / acute myeloid leukemia. In addition its use can produce pneumonitis.
Embryofetal toxicity. Do not use during pregnancy or in women of childbearing potential who do not use reliable contraception during therapy and for one month after receiving the last dose.
Olaparib decreases appetite and causes headache, dizziness, dysgeusia, nausea, vomiting, diarrhea, dyspepsia, fatigue.
Blood disorders: anemia, neutropenia, lymphopenia, increase in blood creatinine and elevation of mean corpuscular volume.
Gene or region studied